(S)-Vigabatrin is a pharmaceutical compound primarily used as an anticonvulsant in the treatment of epilepsy, particularly for patients who do not respond to other medications. It is a derivative of gamma-aminobutyric acid (GABA) and functions as an irreversible inhibitor of the enzyme GABA transaminase, leading to increased levels of GABA in the brain, which helps to stabilize neuronal activity. The compound is characterized by its chiral nature, with the (S)-enantiomer being the active form responsible for its therapeutic effects. In terms of physical properties, (S)-Vigabatrin is typically a white to off-white crystalline powder, soluble in water, and has a specific melting point range. Its chemical structure includes a cyclopropane ring, contributing to its unique pharmacological profile. While effective, it is important to monitor for potential side effects, including visual field defects, and it is contraindicated in certain populations. Overall, (S)-Vigabatrin represents a significant advancement in the management of refractory epilepsy.

(S)-Vigabatrin

74046-07-4: (+)-γ-Vinyl GABA, (4S)-4-Amino-5-hexenoic acid, (S)-(+)-Gamma-vinyl-GABA, (S)-4-Amino-5-hexenoic acid, (S)-Vigabatrin, 4(S)-Amino-5-hexenoic acid, 5-Hexenoic acid, 4-amino-, (4S)-, 5-Hexenoic acid, 4-amino-, (S)-, Rmi 71890, (4S)-4-Aminohex-5-enoic acid

S(+)-4-AMINOHEXENOIC ACID

Inhibitor of GABA transaminase; anti-convulsant

S(+)-γ-Vinyl-GABA

Applications Vigabatrin is a novel anti-epileptic drug. Antidepressant; antipsychotic; anxiolytic.
References Vajda, F., et al.: Clin. Neurosci., 7, 88 (2000), Beghi, E., et al.: Lancet. Neurol., 3, 618 (2004), Sagirli, O., et al.: J. Pharmaceut. Biomed., 42, 618 (2006),


CAS 74046-07-4: (S)-Vigabatrin

S(+)-4-AMINOHEXENOIC ACID

Ref: IN-DA00FDS4

(S)-Vigabatrin

Ref: 3D-FV28693

S(+)-γ-Vinyl-GABA

Ref: 10-M02662

(S)-Vigabatrin

Ref: TR-V253000